National Institute of Neurological Disorders and Stroke (NINDS): Multiple Sclerosis trials

The registry lists 30 Multiple Sclerosis studies with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor. 5 are open to participants now and 4 have results posted.

Phase 1 8Phase 2 11Phase 3 2No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyRecruitingNCT05849467Phase 1
• Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesRecruitingNCT02784210Phase 2
• Pathological Basis of MRI Signal Changes in Multiple SclerosisRecruitingNCT02659956
• Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)RecruitingNCT01730131
• Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)RecruitingNCT00001248
• Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple SclerosisActive, not recruitingNCT04742400Phase 2Results posted
• Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple SclerosisCompletedNCT04025554Phase 1/2Results posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic DysphagiaCompletedNCT00376506Phase 2Results posted
• In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance ImagingCompletedNCT02511028Phase 1
• Natural History of Multiple Sclerosis and Its MimickersCompletedNCT02504840
• Oral Guanabenz for Multiple SclerosisTerminatedNCT02423083Phase 1
• Natural History of Optic NeuritisTerminatedNCT01851434
• Relating Genetic and Environmental Risk Scores to Multiple Sclerosis SusceptibilityCompletedNCT01617395
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedNCT01326715Phase 1
• Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)CompletedNCT01143441Phase 1
• Brain Peripheral Benzodiazepine Receptors in Patients With Multiple SclerosisCompletedNCT00432900Phase 1
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00393588
• Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple SclerosisCompletedNCT00342134Phase 2
• Biomarkers in Multiple SclerosisCompletedNCT00325988
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00321568
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00099307
• Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT00071838Phase 2
• Rolipram to Treat Multiple SclerosisCompletedNCT00011375Phase 2
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple SclerosisCompletedNCT00004744Phase 3
• Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneStatus unknownNCT00004645Phase 3
• Zenapax to Treat Multiple SclerosisCompletedNCT00001934Phase 2
• Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)CompletedNCT00001781Phase 2
• A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) PatientsCompletedNCT00001669Phase 2
• Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT00001156